ArticleAbdominal radiology (New York)2026
Diagnostic performance of diffusion-weighted imaging with quantitative apparent diffusion coefficient for detecting residual or recurrent hepatocellular carcinoma after TACE: a meta-analysis.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate detection of residual or recurrent hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) is critical for guiding subsequent management but remains challenging with conventional imaging. Diffusion-weighted imaging (DWI) with quantitative apparent diffusion coefficient (ADC) has emerged as a functional MRI technique that may improve diagnostic accuracy in this setting, though evidence remains heterogeneous.
objectiveTo assess the diagnostic performance of DWI combined with quantitative ADC for identifying residual or recurrent HCC following TACE.
methodsA literature search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted for studies published up to September 2025. Pooled estimates for sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curve metrics were derived using a bivariate random-effects model to account for anticipated heterogeneity.
resultsThe meta-analysis included 16 studies, encompassing 818 patients and 971 lesions. The pooled sensitivity was 0.78 (95% CI: 0.70-0.85), and the pooled specificity was 0.83 (95% CI: 0.77-0.87). The pooled PLR was 4.53 (95% CI: 3.28-6.26), the NLR was 0.26 (95% CI: 0.18-0.37), and the DOR was 13.89 (95% CI: 8.46-22.82). The area under the SROC curve was 0.88 (95% CI: 0.85-0.90). Subgroup analysis indicated that the diagnostic accuracy (AUC) was significantly higher in prospective studies compared to retrospective studies.
conclusionsDWI with quantitative ADC demonstrates good overall diagnostic accuracy for detecting residual or recurrent HCC after TACE. The technique offers moderate-to-high specificity but more modest sensitivity, and should currently be considered a complementary adjunct to conventional imaging rather than a standalone replacement. REGISTRATION: The review protocol was registered on INPLASY platform (Registration number: INPLASY2025100047).
Indexed as
Identifiers
42789050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.